Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Mallinckrodt
McKesson
Baxter
Merck

Last Updated: May 28, 2022

PROBUPHINE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Probuphine, and what generic alternatives are available?

Probuphine is a drug marketed by Titan Pharms and is included in one NDA. There is one patent protecting this drug.

This drug has sixteen patent family members in thirteen countries.

The generic ingredient in PROBUPHINE is buprenorphine hydrochloride. There are twenty-nine drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the buprenorphine hydrochloride profile page.

Summary for PROBUPHINE
International Patents:16
US Patents:1
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 12
Clinical Trials: 8
Patent Applications: 4,261
Formulation / Manufacturing:see details
Drug Prices: Drug price information for PROBUPHINE
What excipients (inactive ingredients) are in PROBUPHINE?PROBUPHINE excipients list
DailyMed Link:PROBUPHINE at DailyMed
Drug patent expirations by year for PROBUPHINE
Drug Prices for PROBUPHINE

See drug prices for PROBUPHINE

Recent Clinical Trials for PROBUPHINE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Medical College of WisconsinPhase 2
Braeburn PharmaceuticalsPhase 3
National Institute on Drug Abuse (NIDA)Phase 3

See all PROBUPHINE clinical trials

US Patents and Regulatory Information for PROBUPHINE

PROBUPHINE is protected by one US patents.

Patents protecting PROBUPHINE

Implantable polymeric device for sustained release of buprenorphine
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: FOR OPIOID DEPENDENCE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Titan Pharms PROBUPHINE buprenorphine hydrochloride IMPLANT;IMPLANTATION 204442-001 May 26, 2016 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for PROBUPHINE

See the table below for patents covering PROBUPHINE around the world.

Country Patent Number Title Estimated Expiration
Japan 4668611 See Plans and Pricing
Japan 2005528422 See Plans and Pricing
European Patent Office 1509182 DISPOSITIF POLYMERE IMPLANTABLE PERMETTANT LA LIBERATION PROLONGEE DE BUPRENORPHINE (IMPLANTABLE POLYMERIC DEVICE FOR SUSTAINED RELEASE OF BUPRENORPHINE) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Mallinckrodt
Moodys
Dow
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.